Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2003, Vol. 1 ›› Issue (2): 151-154.doi: 10.3736/jcim20030221

Previous Articles     Next Articles

Evidence-based medicine and treatment of lung cancer

Zhen-ye Xu()   

  1. Department of Tumor, Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 20032,China
  • Received:2003-01-09 Online:2003-06-20 Published:2018-10-19

Traditional Chinese medicine (TCM) thinks highly of Zheng Hou in the treatment of lung cancer. Zheng is evidence. Hou is clinical manifestations. After obtaining information and evidence of patients by means of the four diagnostic methods, doctors treat patients by syndrome differentiation. In TCM, the collection and study of medical literature of tumor are emphasized. Medical classics and successful treatment of certain cases are used to guide clinical treatment. Such practice of TCM is similar to that of evidence-based medicine (EBM). Oncology of TCM and EBM are all of ancient origin. There are many clinical reports of satisfactory curative effects in treating lung cancer by TCM. But there are still many problems in methodology, such as careless random method, incomparability in base line, and deficiency of large exponent, multicenter, blind method or randomization. Sometimes the effects of control drugs are incredible. The determination of near effect is not strict. There are exponent errors in statistics of near effect (CR+PR). Certainly, treatment of lung cancer by TCM has its uniqueness. The main characteristic of treatment by TCM is that it can restrain or slow the growth of tumor. At the same time, physical signs, symptoms and quality of life can be improved, and survival period is prolonged. "Survival rate is the golden standard". If we can explore a new treatment strategy to control the growth and metastasis of advanced NSCLC and prevent relapse and metastasis of earlier period or metaphase NSCLC by the method of binding TCM and west medicine under the rules of EBM, such as multicenter (TCM hospital and western medicine hospital),blind method, strict randomization and control, the conclusion of the study will be more scientific.

Key words: evidence-based medicine, lung cancer, therapeutics, traditional Chinese medicine

CLC Number: 

  • R242
[1] Cox JD, Azarnia N, Byhardt RW , et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11[J]. J Clin Oncol, 1990,8(9):1543-1555
doi: 10.1200/JCO.1990.8.9.1543
[2] Sandler HM, Curran WJ Jr, Turrisi AT 3rd . The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 1990,19(1):9-13
doi: 10.1016/0360-3016(90)90127-6
[3] Dosoretz DE, Galmarini D, Rubenstein JH , et al. Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication[J]. Int J Radiat Oncol Biol Phys, 1993,27(3):507-516
doi: 10.1016/0360-3016(93)90373-4
[4] Sawyer TE, Bonner JA, Gould PM , et al. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks[J]. Ann Thorac Surg, 1997, 64(5):1402-1407; discussion, 1407-1408
[5] Mayer R, Smolle-Juettner FM, Szolar D , et al. Post-operative radiotherapy in radically resected non-small cell lung cancer[J]. Chest, 1997,112(4):954-959
doi: 10.1378/chest.112.4.954 pmid: 9377958
[6] The Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stageⅡand stage Ⅲ epidermoid cancer of the lung[J]. N Engl J Med, 1986,315(22):1377-1381
[7] Stephens RJ, Girling DJ, Bleehen NM , et al. The role of postoperative radiotherapy in non-small cell lung cancer: a multicenter randomized trial in patients with pathologically staged T1-2,N1-2,M0 disease[J]. Br J Cancer, 1996,74(4):632-639
doi: 10.1038/bjc.1996.413
[8] 钱浩, 蒋国梁, 王丽娟 , 等. 非小细胞肺癌术后放疗511例分析[J]. 中华放射肿瘤学杂志, 1993,2(4):235-237
[9] 王瑞芝, 李明淑, 邓晓芹 , 等. 非小细胞肺癌不同治疗方法分析[J]. 中华放射肿瘤学杂志, 1995,4(1):34-36
[10] Liberati A. The potential and limitations of evidence-based medicine[A]. In: Asco Educational Book[M]. 1998. 446-450.
[11] 吴一龙 . 肺癌临床研究的方式、方法、方向[J]. 医学与哲学, 2000,21(3):1-5
doi: 10.3969/j.issn.1002-0772.2000.03.001
[12] 赖世隆, 胡镜清, 郭新峰 . 循证医学与中医药临床研究[J]. 广州中医药大学学报, 2000,17(1):1-8
doi: 10.3969/j.issn.1007-3213.2000.01.001
[13] 陈可翼, 宋军 . 循证医学的提出对中西医结合的启发[J]. 中国中西医结合杂志, 1999,19(11):643-644
doi: 10.3321/j.issn:1003-5370.1999.11.001
[14] 沙慧芳, 苏建中, 包国良, 等. 小鼠Lewis肺癌耐药细胞株的逆转研究[A]. 见: 中国肿瘤耐药与肿瘤化疗研究进展 (全国肿瘤耐药与肿瘤化疗药物应用学术会议论文汇编)[C]. 2001. 149.
[1] Sherman Gu, Arthur Yin Fan. Controversial conclusions from two randomized controlled trials for acupuncture's effects on polycystic ovary syndrome or in vitro fertilization support. Journal of Integrative Medicine, 2020, 18(2): 89-91.
[2] Xue-qing Yu, Shu-guang Yang, Yang Xie, Jian-sheng Li. Traditional Chinese medicine in the treatment of idiopathic pulmonary fibrosis based on syndrome differentiation: Study protocol of exploratory trial. Journal of Integrative Medicine, 2020, 18(2): 163-168.
[3] Chang-quan Ling. Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2). Journal of Integrative Medicine, 2020, 18(2): 87-88.
[4] Wen Qiang Lee, Jeremy Teoh, Pei Zheng Kenneth Lee, Zhi Xiong Gerard Low, Xueling Sim, Foong Fong Mary Chong, Norbert Ludwig Wagner. Factors influencing communication of traditional Chinese medicine use between patients and doctors: a multisite cross-sectional study. Journal of Integrative Medicine, 2019, 17(6): 396-403.
[5] Mikhail Teppone. Medicine has always been “Modern” and “Scientific” from ancient times to the present day. Journal of Integrative Medicine, 2019, 17(4): 229-237.
[6] Charles Dalcanale Tesser, Ari Ojeda Ocampo Moré, Melissa Costa Santos, Emiliana Domingues Cunha da Silva, Fátima Terezinha Pelachini Farias, Lúcio José Botelho. Auriculotherapy in primary health care: A large-scale educational experience in Brazil. Journal of Integrative Medicine, 2019, 17(4): 302-309.
[7] Rachael Farrington, Ian F.Musgrave, Roger W.Byard. Evidence for the efficacy and safety of herbal weight loss preparations. Journal of Integrative Medicine, 2019, 17(2): 87-92.
[8] Fung-Kei Cheng. An overview of the contribution of acupuncture to thyroid disorders. Journal of Integrative Medicine, 2018, 16(6): 375-383.
[9] Goulnar Kasymjanova, Anh-Thi Tran, Victor Cohen, Carmela Pepe, Lama Sakr, David Small, Jason Scott Agulnik, Robert Thomas Jagoe. The use of a standardized Chinese herbal formula in patients with advanced lung cancer: A feasibility study. Journal of Integrative Medicine, 2018, 16(6): 390-395.
[10] Chang-quan Ling, Jia Fan, Hong-sheng Lin, Feng Shen, Zhen-ye Xu, Li-zhu Lin, Shu-kui Qin, Wei-ping Zhou, Xiao-feng Zhai, Bai Li, Qing-hui Zhou, on behalf of the Chinese Integrative Therapy of Primary Liver Cancer Working Group. Clinical practice guidelines for the treatment of primary liver cancer with integrative traditional Chinese and Western medicine. Journal of Integrative Medicine, 2018, 16(4): 236-248.
[11] Shui-jie Shen, Yong-hong Zhang, Xiao-xia Gu, Shui-ju Jiang, Ling-jun Xu. Yangfei Kongliu Formula, a compound Chinese herbal medicine, combined with cisplatin, inhibits growth of lung cancer cells through transforming growth factor-β1 signaling pathway. Journal of Integrative Medicine, 2017, 15(3): 242-251.
[12] Qing Ji, Yun-quan Luo, Wen-hai Wang, Xuan Liu, Qi Li, Shi-bing Su. Research advances in traditional Chinese medicine syndromes in cancer patients. Journal of Integrative Medicine, 2016, 14(1): 12-21.
[13] Bing He, Ge Zhang, Ai-ping Lu. Integrative network analysis: Bridging the gap between Western medicine and traditional Chinese medicine. Journal of Integrative Medicine, 2015, 13(3): 133-135.
[14] Zhao-guo Li, Xi-ru Liu. Comparative study on WHO Western Pacific Region and World Federation of Chinese Medicine Societies international standard terminologies on traditional medicine: Diseases of Paediatrics (Part 3). Journal of Integrative Medicine, 2015, 13(3): 201-204.
[15] Xiao Ye, Jing Wang. On English translation of infant Tuina points in traditional Chinese medicine. Journal of Integrative Medicine, 2015, 13(3): 205-207.
Full text



No Suggested Reading articles found!